Patient Square Capital
Latest statistics and disclosures from Patient Square Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are ROIV, INSM, MIRM, ARGX, ONC, and represent 62.12% of Patient Square Capital's stock portfolio.
- Added to shares of these 10 stocks: ONC (+$21M), MIRM (+$15M), TERN (+$13M), COGT (+$11M), ARGX (+$8.8M), DBVT (+$6.9M), XENE (+$6.1M), ARQT (+$6.1M), PHVS (+$5.5M), SYRE.
- Started 9 new stock positions in XENE, RCUS, ONC, COGT, HROW, TERN, ARQT, DBVT, SYRE.
- Reduced shares in these 10 stocks: ROIV (-$94M), CDTX (-$12M), INSM (-$10M), LQDA (-$6.0M), AGIO (-$5.4M), QURE, EYPT, NRIX, ABVX, OCUL.
- Sold out of its positions in AGIO, CDTX, GERN, NRIX, QURE.
- Patient Square Capital was a net seller of stock by $-27M.
- Patient Square Capital has $467M in assets under management (AUM), dropping by 24.95%.
- Central Index Key (CIK): 0001819257
Tip: Access up to 7 years of quarterly data
Positions held by Patient Square Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Patient Square Capital
Patient Square Capital holds 28 positions in its portfolio as reported in the December 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Roivant Sciences SHS (ROIV) | 37.9 | $177M | -34% | 8.2M | 21.70 |
|
| Insmed Com Par $.01 (INSM) | 9.9 | $47M | -18% | 267k | 174.04 |
|
| Mirum Pharmaceuticals (MIRM) | 5.1 | $24M | +186% | 299k | 78.99 |
|
| Argenx Se Sponsored Adr (ARGX) | 4.7 | $22M | +67% | 26k | 840.95 |
|
| Beone Medicines Sponsored Ads (ONC) | 4.5 | $21M | NEW | 69k | 303.81 |
|
| Abivax Sa Sponsored Ads (ABVX) | 3.8 | $18M | -14% | 130k | 134.85 |
|
| Pharvaris N V (PHVS) | 3.2 | $15M | +57% | 543k | 27.75 |
|
| Eyepoint Com New (EYPT) | 3.1 | $14M | -22% | 780k | 18.27 |
|
| Terns Pharmaceuticals (TERN) | 2.8 | $13M | NEW | 320k | 40.40 |
|
| Celcuity (CELC) | 2.6 | $12M | +20% | 120k | 99.74 |
|
| Cogent Biosciences (COGT) | 2.4 | $11M | NEW | 317k | 35.52 |
|
| Kymera Therapeutics (KYMR) | 2.3 | $11M | +50% | 139k | 77.81 |
|
| Liquidia Corporation Com New (LQDA) | 1.7 | $7.8M | -43% | 227k | 34.49 |
|
| Dbv Technologies S A Sponsored Ads (DBVT) | 1.5 | $6.9M | NEW | 359k | 19.17 |
|
| Allogene Therapeutics (ALLO) | 1.5 | $6.8M | +66% | 5.0M | 1.37 |
|
| Dianthus Therapeutics (DNTH) | 1.3 | $6.2M | +20% | 150k | 41.21 |
|
| Xenon Pharmaceuticals (XENE) | 1.3 | $6.1M | NEW | 137k | 44.82 |
|
| Arcutis Biotherapeutics (ARQT) | 1.3 | $6.1M | NEW | 210k | 29.04 |
|
| Ocular Therapeutix (OCUL) | 1.3 | $5.9M | -31% | 490k | 12.14 |
|
| Disc Medicine (IRON) | 1.3 | $5.9M | 74k | 79.41 |
|
|
| Avalo Therapeutics Com New (AVTX) | 1.2 | $5.7M | +211% | 312k | 18.16 |
|
| Spyre Therapeutics Com New (SYRE) | 1.1 | $4.9M | NEW | 150k | 32.76 |
|
| Enliven Therapeutics (ELVN) | 1.0 | $4.7M | +22% | 308k | 15.40 |
|
| Assembly Biosciences Com New (ASMB) | 0.9 | $4.3M | -6% | 127k | 34.01 |
|
| Amylyx Pharmaceuticals (AMLX) | 0.9 | $4.2M | +10% | 350k | 12.08 |
|
| Arcus Biosciences Incorporated (RCUS) | 0.9 | $4.1M | NEW | 170k | 23.83 |
|
| Perspective Therapeutics Com New (CATX) | 0.7 | $3.1M | +224% | 1.1M | 2.75 |
|
| Harrow Health (HROW) | 0.1 | $345k | NEW | 7.0k | 49.00 |
|
Past Filings by Patient Square Capital
SEC 13F filings are viewable for Patient Square Capital going back to 2022
- Patient Square Capital 2025 Q4 filed Feb. 12, 2026
- Patient Square Capital 2025 Q3 filed Nov. 10, 2025
- Patient Square Capital 2025 Q2 filed Aug. 11, 2025
- Patient Square Capital 2025 Q1 filed May 14, 2025
- Patient Square Capital 2024 Q4 filed Feb. 14, 2025
- Patient Square Capital 2024 Q3 filed Nov. 14, 2024
- Patient Square Capital 2024 Q1 filed May 14, 2024
- Patient Square Capital 2023 Q4 filed Feb. 13, 2024
- Patient Square Capital 2023 Q3 filed Nov. 14, 2023
- Patient Square Capital 2023 Q2 filed Aug. 11, 2023
- Patient Square Capital 2023 Q1 filed May 10, 2023
- Patient Square Capital 2022 Q4 filed Feb. 13, 2023